Lantus Market Report 2026

Lantus Market Overview

• The Lantus market growth in the historic period has been driven by rising prevalence of diabetes globally, advancements in insulin formulation science • Market expansion is supported by growing competition from biosimilar insulins, increasing focus on personalized insulin therapy • Growth Driver: Rising Prevalence Of Diabetes Fuels Market Growth • Market Trend: Expansion Of Insulin Production Facilities To Meet Growing Demand • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lantus Market?

Lantus refers to a long-acting insulin formulation known as insulin glargine. It is used primarily to manage blood sugar levels in individuals with diabetes. Lantus helps to control blood glucose over a 24-hour period by providing a steady and consistent release of insulin, mimicking the natural insulin secretion in the body. The main types of indications for lantus are treatment of type 1 diabetes, treatment of type 2 diabetes, and management of hyperglycemia. Treatment of type 1 diabetes involves insulin therapy, with Lantus providing a 24-hour basal insulin to help maintain stable blood glucose levels and prevent fluctuations. It is available in various formulations, such as injectable formulation (solution for injection), and pre-filled pens (lantus solostar). It is distributed through various channels such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and is used by various end users including hospitals, diabetes clinics, specialty clinics, and home healthcare providers.

What Is The Lantus Market Growth Forecast?

The growth in the forecast period can be attributed to growing competition from biosimilar insulins, increasing focus on personalized insulin therapy, expansion of digital diabetes management tools, rising demand for cost-effective insulin options, continued innovation in insulin delivery. Major trends in the forecast period include increasing adoption of long-acting insulin analogues, expansion of diabetes management programs, growing preference for once-daily insulin regimens, enhanced focus on glycemic stability, rising use of pre-filled insulin delivery devices.

Global Lantus Market Segmentation

1) By Indication: Treatment Of Type 1 Diabetes, Treatment Of Type 2 Diabetes, Management Of Hyperglycemia 2) By Formulation: Injectable Formulation (Solution For Injection), Pre-Filled Pens (Lantus SoloStar) 3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End Use: Hospitals, Diabetes Clinics, Specialty Clinics, Home Healthcare Providers

What Are The Drivers Of The Lantus Market?

The increasing prevalence of diabetes is expected to propel the growth of the lantus market going forward. Diabetes refers to a chronic medical condition where the body either does not produce enough insulin or cannot effectively use the insulin it produces, leading to high blood sugar levels. The increasing prevalence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, rising obesity rates, genetic predisposition, and an aging population. Lantus is beneficial for diabetes as it provides long-acting, consistent blood sugar control for up to 24 hours, reducing the risk of glucose fluctuations and helping patients maintain stable glucose levels with fewer daily injections. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, as of March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in 2022. Therefore, the increasing prevalence of diabetes is driving the growth of the lantus industry. The rising geriatric population is expected to boost the growth of the lantus market going forward. The geriatric population refers to individuals aged 65 years and older, often considered in studies and services addressing aging-related health, social, and economic challenges. The rising geriatric population is attributed to increased life expectancy, improved healthcare systems, and declining fertility rates globally. Lantus (insulin glargine) supports the geriatric population by offering long-acting blood sugar regulation, helping to minimize the risk of complications associated with hyperglycemia in older adults with diabetes. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, the UK had 12.7 million people aged 65 or older, accounting for 19% of the total population. By 2072, this figure is projected to rise to 22.1 million, representing 27% of the population. Therefore, the rising geriatric population is driving the growth of lantus industry.

Key Players In The Global Lantus Market

Major companies operating in the lantus market are Sanofi S.A.

Global Lantus Market Trends and Insights

The key trend in the lantus market is focusing on facility expansion to increase the production of insulin products. Facility expansion for insulin production typically involves increasing manufacturing capacity, upgrading equipment, and optimizing processes to meet growing demand for insulin. For instance, in August 2024, Sanofi S.A., a France-based pharmaceutical industry company, invested $1.40 billion (1.3 billion euros) in a new insulin production facility at its existing site in Frankfurt. The investment aims to expand Sanofi's insulin production capabilities at its Frankfurt BioCampus, boosting the manufacturing capacity for Lantus and other insulin products. This will help meet the growing demand for diabetes treatments and ensure a stable global supply, reinforcing the company's commitment to supporting diabetes care worldwide.

Regional Insights

North America was the largest region in the lantus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Lantus Market?

The lantus market consists of sales of lantus solostar, lantus vials, and toujeo. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lantus Market Report 2026?

The lantus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lantus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.